유방 영상 진단 분야 AI 시장 : 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of AI in breast imaging Market

The global AI in breast imaging market is witnessing rapid growth due to the increasing adoption of artificial intelligence in breast cancer screening, growing demand for early disease detection, and rising pressure on radiologists to manage expanding imaging workloads. According to the report, the global AI in breast imaging market size was valued at USD 842.5 million in 2025. The market is projected to grow from USD 1,090.6 million in 2026 to USD 8,600.0 million by 2034, exhibiting a CAGR of 29.45% during the forecast period. North America dominated the market with a 41.99% share in 2025, driven by widespread adoption of digital mammography, AI-enabled diagnostic workflows, favorable regulatory approvals, and strong investments in healthcare technology.

AI in breast imaging comprises advanced software solutions and related services that support mammography, digital breast tomosynthesis (DBT), breast ultrasound, and MRI by improving lesion detection, breast density assessment, workflow prioritization, and reporting accuracy. Increasing breast cancer screening rates and the growing need for faster, more consistent diagnosis continue to fuel market expansion.

Market Definition and Scope

AI in breast imaging integrates machine learning, computer vision, and deep learning algorithms into breast imaging workflows to improve diagnostic accuracy and clinical efficiency. These AI-powered solutions assist radiologists in detecting suspicious lesions, evaluating dense breast tissue, prioritizing high-risk cases, and reducing false-negative results.

The market covers AI software, implementation and support services, cloud-based, on-premise, and hybrid deployment models, along with technologies such as computer vision, machine learning, and natural language processing. Applications include cancer detection & triage, breast density assessment, workflow prioritization, reporting support, and risk stratification across hospitals, diagnostic imaging centers, breast screening facilities, and research institutes.

Market Dynamics

Drivers

The increasing demand for early breast cancer detection is the primary driver of market growth. Rising breast cancer incidence, expanding national screening programs, and the need to detect cancers at earlier and more treatable stages are encouraging hospitals and imaging centers to adopt AI-assisted diagnostic tools. AI enhances radiologists' productivity by identifying subtle abnormalities, reducing missed diagnoses, and improving overall screening efficiency.

Trends

A major market trend is the growing adoption of AI-powered diagnostic technologies integrated into mammography, DBT, ultrasound, and MRI workflows. AI solutions are evolving beyond lesion detection to include breast density assessment, workflow optimization, and personalized risk prediction. Increasing regulatory approvals and successful real-world clinical studies are further accelerating adoption across healthcare systems.

Restraints

High implementation costs remain a major restraint for the market. Deploying AI requires investment in PACS/RIS integration, cloud infrastructure, cybersecurity, workflow redesign, software maintenance, and radiologist training. Limited reimbursement policies and high deployment costs continue to discourage adoption among smaller healthcare providers.

Opportunities

The expansion of AI-assisted 3D breast tomosynthesis (DBT) presents significant growth opportunities. As healthcare providers increasingly adopt DBT for superior breast tissue visualization, demand for AI tools capable of analyzing large volumes of 3D imaging data is rising rapidly. AI-assisted DBT improves diagnostic accuracy while reducing radiologists' reading time.

Challenges

Limited availability of high-quality annotated imaging datasets remains one of the industry's biggest challenges. Developing accurate AI algorithms requires extensive clinically validated mammography, ultrasound, MRI, and DBT datasets with expert annotations, making model development time-consuming and expensive.

Segmentation Analysis

By component, the software segment dominated the market in 2025 owing to increasing adoption of AI-powered diagnostic platforms integrated with PACS, cloud systems, and mammography workstations. Services are expected to experience steady growth as implementation and consulting demand increases.

By deployment, the cloud-based segment led the market due to its scalability, lower infrastructure investment, centralized software updates, and easier enterprise-wide deployment.

By technology, computer vision dominated the market as it plays a critical role in analyzing mammography, DBT, ultrasound, and MRI images for cancer detection and lesion identification.

By modality, mammography and digital breast tomosynthesis (DBT) accounted for the largest market share owing to their widespread use in routine breast cancer screening programs.

By application, cancer detection & triage remained the leading segment due to increasing clinical evidence demonstrating AI's ability to improve cancer detection rates while reducing radiologists' workload.

By end user, hospitals & health systems dominated the market because of their high imaging volumes, advanced digital infrastructure, and growing partnerships with AI solution providers.

Regional Insights

North America dominated the global AI in breast imaging market with a valuation of USD 353.8 million in 2025, supported by extensive adoption of AI-enabled mammography, digital breast tomosynthesis, advanced healthcare infrastructure, and favorable FDA approvals. Europe is expected to witness strong growth due to organized national screening programs and increasing regulatory acceptance of AI-enabled diagnostic technologies. Asia Pacific is projected to expand rapidly with growing breast cancer awareness, improving diagnostic infrastructure, and increasing investments in AI-based medical imaging across China, India, and Japan. Latin America and the Middle East & Africa are expected to experience steady growth as governments strengthen cancer screening programs and healthcare modernization initiatives.

Competitive Landscape

The global market is moderately fragmented, with companies focusing on regulatory approvals, AI innovation, workflow integration, and strategic partnerships. Major players include Hologic, Inc., GE HealthCare, Lunit Inc., RadNet (DeepHealth), ScreenPoint Medical B.V., CureMetrix, Clairity, Whiterabbit, Densitas Inc., and Therapixel. These companies continue expanding their AI portfolios through product innovation, cloud-based solutions, strategic collaborations, and clinical validation studies to strengthen their market positions.

Report Coverage

The report provides a comprehensive analysis of the global AI in breast imaging market, covering market size for 2025, 2026, and 2034, along with market dynamics, key drivers, restraints, opportunities, challenges, segmentation by component, deployment, technology, modality, application, and end user. It also includes regional analysis, competitive landscape, company profiles, regulatory developments, mergers & acquisitions, product launches, and recent technological advancements shaping the industry.

Conclusion

The global AI in breast imaging market is poised for exceptional growth, expanding from USD 842.5 million in 2025 to USD 1,090.6 million in 2026, and reaching USD 8,600.0 million by 2034. Rising breast cancer screening rates, increasing adoption of AI-powered diagnostic technologies, advancements in digital breast tomosynthesis, and growing demand for early disease detection will continue driving market expansion. Despite challenges related to implementation costs and data availability, continuous innovation, regulatory approvals, and broader clinical integration are expected to create substantial long-term opportunities for AI solution providers worldwide.

Segmentation By Component, Deployment, Technology, Modality, Application, End User, and Region

By Component * Software

• Services

By Deployment * Cloud-Based

• On-Premise
• Hybrid

By Technology * Computer Vision

• Machine Learning & Deep Learning
• Natural Language Processing (NLP)
• Others

By Modality * Mammography/DBT

• Breast Ultrasound
• Breast MRI
• Multi-modality
• Others

By Application * Cancer Detection & Triage

• Breast Density Assessment
• Risk Stratification
• Workflow Prioritization
• Reporting & Quality Support
• Others

By End User * Hospitals & Health Systems

• Diagnostic Imaging Centers
• Breast Screening Centers
• Academic & Research Institutes
• Others

By Region * North America (By Component, Deployment, Technology, Modality, Application, End User, and Country)

• U.S.
• Canada
• Europe (By Component, Deployment, Technology, Modality, Application, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Component, Deployment, Technology, Modality, Application, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Component, Deployment, Technology, Modality, Application, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Component, Deployment, Technology, Modality, Application, End User, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Challenges
• 3.5. Market Trends

4. Key Insights

• 4.1. Technological Advancements in AI in Breast Imaging
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Key Start-ups in this market

5. Global AI in Breast Imaging Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Component
  • 5.1.1. Software
  • 5.1.2. Services
• 5.2. Market Analysis, Insights and Forecast - By Deployment
  • 5.2.1. Cloud-Based
  • 5.2.2. On-Premise
  • 5.2.3. Hybrid
• 5.3. Market Analysis, Insights and Forecast - By Technology
  • 5.3.1. Computer Vision
  • 5.3.2. Machine Learning & Deep Learning
  • 5.3.3. Natural Language Processing (NLP)
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Modality
  • 5.4.1. Mammography/DBT
  • 5.4.2. Breast Ultrasound
  • 5.4.3. Breast MRI
  • 5.4.4. Multi-modality
  • 5.4.5. Others
• 5.5. Market Analysis, Insights and Forecast - By Application
  • 5.5.1. Cancer Detection & Triage
  • 5.5.2. Breast Density Assessment
  • 5.5.3. Risk Stratification
  • 5.5.4. Workflow Prioritization
  • 5.5.5. Reporting & Quality Support
  • 5.5.6. Others
• 5.6. Market Analysis, Insights and Forecast - By End User
  • 5.6.1. Hospitals & Health Systems
  • 5.6.2. Diagnostic Imaging Centers
  • 5.6.3. Breast Screening Centers
  • 5.6.4. Academic & Research Institutes
  • 5.6.5. Others
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America AI in Breast Imaging Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Component
  • 6.1.1. Software
  • 6.1.2. Services
• 6.2. Market Analysis, Insights and Forecast - By Deployment
  • 6.2.1. Cloud-Based
  • 6.2.2. On-Premise
  • 6.2.3. Hybrid
• 6.3. Market Analysis, Insights and Forecast - By Technology
  • 6.3.1. Computer Vision
  • 6.3.2. Machine Learning & Deep Learning
  • 6.3.3. Natural Language Processing (NLP)
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Modality
  • 6.4.1. Mammography/DBT
  • 6.4.2. Breast Ultrasound
  • 6.4.3. Breast MRI
  • 6.4.4. Multi-modality
  • 6.4.5. Others
• 6.5. Market Analysis, Insights and Forecast - By Application
  • 6.5.1. Cancer Detection & Triage
  • 6.5.2. Breast Density Assessment
  • 6.5.3. Risk Stratification
  • 6.5.4. Workflow Prioritization
  • 6.5.5. Reporting & Quality Support
  • 6.5.6. Others
• 6.6. Market Analysis, Insights and Forecast - By End User
  • 6.6.1. Hospitals & Health Systems
  • 6.6.2. Diagnostic Imaging Centers
  • 6.6.3. Breast Screening Centers
  • 6.6.4. Academic & Research Institutes
  • 6.6.5. Others
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe AI in Breast Imaging Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Component
  • 7.1.1. Software
  • 7.1.2. Services
• 7.2. Market Analysis, Insights and Forecast - By Deployment
  • 7.2.1. Cloud-Based
  • 7.2.2. On-Premise
  • 7.2.3. Hybrid
• 7.3. Market Analysis, Insights and Forecast - By Technology
  • 7.3.1. Computer Vision
  • 7.3.2. Machine Learning & Deep Learning
  • 7.3.3. Natural Language Processing (NLP)
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Modality
  • 7.4.1. Mammography/DBT
  • 7.4.2. Breast Ultrasound
  • 7.4.3. Breast MRI
  • 7.4.4. Multi-modality
  • 7.4.5. Others
• 7.5. Market Analysis, Insights and Forecast - By Application
  • 7.5.1. Cancer Detection & Triage
  • 7.5.2. Breast Density Assessment
  • 7.5.3. Risk Stratification
  • 7.5.4. Workflow Prioritization
  • 7.5.5. Reporting & Quality Support
  • 7.5.6. Others
• 7.6. Market Analysis, Insights and Forecast - By End User
  • 7.6.1. Hospitals & Health Systems
  • 7.6.2. Diagnostic Imaging Centers
  • 7.6.3. Breast Screening Centers
  • 7.6.4. Academic & Research Institutes
  • 7.6.5. Others
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific AI in Breast Imaging Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Component
  • 8.1.1. Software
  • 8.1.2. Services
• 8.2. Market Analysis, Insights and Forecast - By Deployment
  • 8.2.1. Cloud-Based
  • 8.2.2. On-Premise
  • 8.2.3. Hybrid
• 8.3. Market Analysis, Insights and Forecast - By Technology
  • 8.3.1. Computer Vision
  • 8.3.2. Machine Learning & Deep Learning
  • 8.3.3. Natural Language Processing (NLP)
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Modality
  • 8.4.1. Mammography/DBT
  • 8.4.2. Breast Ultrasound
  • 8.4.3. Breast MRI
  • 8.4.4. Multi-modality
  • 8.4.5. Others
• 8.5. Market Analysis, Insights and Forecast - By Application
  • 8.5.1. Cancer Detection & Triage
  • 8.5.2. Breast Density Assessment
  • 8.5.3. Risk Stratification
  • 8.5.4. Workflow Prioritization
  • 8.5.5. Reporting & Quality Support
  • 8.5.6. Others
• 8.6. Market Analysis, Insights and Forecast - By End User
  • 8.6.1. Hospitals & Health Systems
  • 8.6.2. Diagnostic Imaging Centers
  • 8.6.3. Breast Screening Centers
  • 8.6.4. Academic & Research Institutes
  • 8.6.5. Others
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Australia
  • 8.7.5. Southeast Asia
  • 8.7.6. Rest of Asia Pacific

9. Latin America AI in Breast Imaging Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Component
  • 9.1.1. Software
  • 9.1.2. Services
• 9.2. Market Analysis, Insights and Forecast - By Deployment
  • 9.2.1. Cloud-Based
  • 9.2.2. On-Premise
  • 9.2.3. Hybrid
• 9.3. Market Analysis, Insights and Forecast - By Technology
  • 9.3.1. Computer Vision
  • 9.3.2. Machine Learning & Deep Learning
  • 9.3.3. Natural Language Processing (NLP)
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Modality
  • 9.4.1. Mammography/DBT
  • 9.4.2. Breast Ultrasound
  • 9.4.3. Breast MRI
  • 9.4.4. Multi-modality
  • 9.4.5. Others
• 9.5. Market Analysis, Insights and Forecast - By Application
  • 9.5.1. Cancer Detection & Triage
  • 9.5.2. Breast Density Assessment
  • 9.5.3. Risk Stratification
  • 9.5.4. Workflow Prioritization
  • 9.5.5. Reporting & Quality Support
  • 9.5.6. Others
• 9.6. Market Analysis, Insights and Forecast - By End User
  • 9.6.1. Hospitals & Health Systems
  • 9.6.2. Diagnostic Imaging Centers
  • 9.6.3. Breast Screening Centers
  • 9.6.4. Academic & Research Institutes
  • 9.6.5. Others
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa AI in Breast Imaging Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Component
  • 10.1.1. Software
  • 10.1.2. Services
• 10.2. Market Analysis, Insights and Forecast - By Deployment
  • 10.2.1. Cloud-Based
  • 10.2.2. On-Premise
  • 10.2.3. Hybrid
• 10.3. Market Analysis, Insights and Forecast - By Technology
  • 10.3.1. Computer Vision
  • 10.3.2. Machine Learning & Deep Learning
  • 10.3.3. Natural Language Processing (NLP)
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Modality
  • 10.4.1. Mammography/DBT
  • 10.4.2. Breast Ultrasound
  • 10.4.3. Breast MRI
  • 10.4.4. Multi-modality
  • 10.4.5. Others
• 10.5. Market Analysis, Insights and Forecast - By Application
  • 10.5.1. Cancer Detection & Triage
  • 10.5.2. Breast Density Assessment
  • 10.5.3. Risk Stratification
  • 10.5.4. Workflow Prioritization
  • 10.5.5. Reporting & Quality Support
  • 10.5.6. Others
• 10.6. Market Analysis, Insights and Forecast - By End User
  • 10.6.1. Hospitals & Health Systems
  • 10.6.2. Diagnostic Imaging Centers
  • 10.6.3. Breast Screening Centers
  • 10.6.4. Academic & Research Institutes
  • 10.6.5. Others
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Hologic, Inc.
  • 11.2.2. General Electric Company
  • 11.2.3. RadNet, Inc. (DeepHealth)
  • 11.2.4. Lunit Inc.
  • 11.2.5. ScreenPoint Medical B.V.
  • 11.2.6. CureMetrix, Inc.
  • 11.2.7. Clairity
  • 11.2.8. Whiterabbit
  • 11.2.9. Densitas Inc.
  • 11.2.10. Therapixel